660847-06-3 Usage
Uses
Used in Pharmaceutical Industry:
HDAC inhibitor is used as a therapeutic agent for the treatment of various diseases, including cancer, neurological disorders, and cardiovascular diseases. It modulates gene expression by inhibiting the deacetylation of histones, leading to changes in chromatin structure and accessibility of DNA to transcription factors.
Used in Cancer Therapy:
HDAC inhibitor is used as an anticancer agent to treat various types of cancer. It can induce cell cycle arrest, promote apoptosis, and inhibit angiogenesis, thereby inhibiting tumor growth and progression. Additionally, it has been shown to enhance the effectiveness of conventional chemotherapy and radiation therapy by increasing the sensitivity of cancer cells to these treatments.
Used in Neurological Disorders:
HDAC inhibitor is used as a potential treatment for neurological disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. It can modulate the expression of genes involved in neuroprotection, synaptic plasticity, and neuronal survival, thereby slowing down or reversing the progression of these disorders.
Used in Cardiovascular Diseases:
HDAC inhibitor is used as a potential treatment for cardiovascular diseases, such as atherosclerosis, hypertension, and heart failure. It can modulate the expression of genes involved in vascular remodeling, inflammation, and fibrosis, thereby reducing the risk of cardiovascular complications.
Check Digit Verification of cas no
The CAS Registry Mumber 660847-06-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,6,0,8,4 and 7 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 660847-06:
(8*6)+(7*6)+(6*0)+(5*8)+(4*4)+(3*7)+(2*0)+(1*6)=173
173 % 10 = 3
So 660847-06-3 is a valid CAS Registry Number.
660847-06-3Relevant academic research and scientific papers
Substrates for efficient fluorometric screening employing the NAD-dependent sirtuin 5 lysine deacylase (KDAC) enzyme
Madsen, Andreas S.,Olsen, Christian A.
, p. 5582 - 5590 (2012/09/21)
The class III lysine deacylases (KDACs), also known as the sirtuins, have emerged as interesting drug targets for therapeutic intervention in a variety of diseases. To gain a deeper understanding of the processes affected by sirtuins, the development of selective small molecule modulators of individual isozymes has been a longstanding goal. Essential for the discovery of novel modulators, however, are good screening protocols and mechanistic insights with regard to the targets in question. We therefore evaluated the activities of the seven human sirtuin hydrolases against a panel of fluorogenic substrates. Both commonly used, commercially available substrates and novel chemotypes designed to address recent developments in the field of lysine post-translational modification were evaluated. Our investigations led to the discovery of two new fluorogenic ε-N-succinyllysine-containing substrates that enable highly efficient and enzyme-economical screening employing sirtuin 5 (SIRT5). Furthermore, optimized protocols for facile kinetic investigations were developed, which should be valuable for enzyme kinetic investigations. Finally, these protocols were applied to a kinetic analysis of the inhibition of SIRT5 by suramin, a potent sirtuin inhibitor previously shown by X-ray crystallography to bind the substrate pocket of the human SIRT5 KDAC enzyme.
